Abstract: Chronic kidney disease(CKD)is a chronic and long-term progressive disease and one of the global public health problems. Renal anemia is one of the common complications of CKD, and its prevalence rate gradually increases with the development of CKD. Renal anemia can lead to tissue ischemia and hypoxia, leading to a series of complications such as respiratory failure and heart failure. At the same time, it aggravates the condition of CKD, and in severe cases, it can endanger patients' lives. Therefore, the correction of renal anemia is a very important part in the treatment of CKD. Routine clinical methods for correcting anemia include supplementing erythropoiesis-stimulants(ESAs), iron, L-carnitineand blood transfusion, but their limitations are increasing. In recent years, hypoxia-inducible factor proline hydroxylase inhibitors, as a new oral drug, has attracted much attention,which has multiple advantages in the treatment of renal anemia, and now it has gradually become a new first-line drug in clinical treatment of renal anemia. This article reviews the recent developments of drug therapy for renal anemia.

Key words: renal anemia, erythropoiesis-stimulating agents, iron agent, L-carnitine, hypoxia-inducible factor proline hydroxylase inhibitor